Alkem Laboratories Ltd. has launched semaglutide in single-shot pre-filled syringes in multiple dose strengths, with prices starting at Rs. 350, marking a significant expansion of treatment options for patients with Type 2 diabetes and obesity in India.

The company stated that it is the first in India to introduce semaglutide in a single-shot pre-filled syringe format. Designed for ready-to-use administration, the new offering aims to improve patient access and convenience while lowering the cost barrier to initiating therapy.

Alkem has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity, to be used alongside diet and exercise.

The launch builds on Alkem’s earlier introduction of semaglutide in pre-filled disposable and reusable injection pen formats in March 2026.

The company has also secured regulatory approval for semaglutide vials and plans to introduce them in the near future, further broadening its portfolio of delivery options for the therapy.

Dr. Vikas Gupta, Chief Executive Officer, Alkem, said, “Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes. In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy.”

Semaglutide, a GLP-1 receptor agonist, has gained global attention for its effectiveness in improving blood sugar control and supporting weight management.